1. Home
  2. SCYX vs VIVK Comparison

SCYX vs VIVK Comparison

Compare SCYX & VIVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • VIVK
  • Stock Information
  • Founded
  • SCYX 1999
  • VIVK 2006
  • Country
  • SCYX United States
  • VIVK United States
  • Employees
  • SCYX N/A
  • VIVK N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • VIVK Oilfield Services/Equipment
  • Sector
  • SCYX Health Care
  • VIVK Energy
  • Exchange
  • SCYX Nasdaq
  • VIVK Nasdaq
  • Market Cap
  • SCYX 36.8M
  • VIVK 34.9M
  • IPO Year
  • SCYX 2014
  • VIVK N/A
  • Fundamental
  • Price
  • SCYX $0.88
  • VIVK $1.14
  • Analyst Decision
  • SCYX
  • VIVK
  • Analyst Count
  • SCYX 0
  • VIVK 0
  • Target Price
  • SCYX N/A
  • VIVK N/A
  • AVG Volume (30 Days)
  • SCYX 204.8K
  • VIVK 1.6M
  • Earning Date
  • SCYX 05-15-2025
  • VIVK 05-20-2025
  • Dividend Yield
  • SCYX N/A
  • VIVK N/A
  • EPS Growth
  • SCYX N/A
  • VIVK N/A
  • EPS
  • SCYX N/A
  • VIVK N/A
  • Revenue
  • SCYX $2,630,000.00
  • VIVK $111,130,140.00
  • Revenue This Year
  • SCYX $460.12
  • VIVK N/A
  • Revenue Next Year
  • SCYX $253.87
  • VIVK N/A
  • P/E Ratio
  • SCYX N/A
  • VIVK N/A
  • Revenue Growth
  • SCYX N/A
  • VIVK 85.84
  • 52 Week Low
  • SCYX $0.72
  • VIVK $0.55
  • 52 Week High
  • SCYX $2.60
  • VIVK $3.45
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 48.64
  • VIVK 69.30
  • Support Level
  • SCYX $0.72
  • VIVK $0.71
  • Resistance Level
  • SCYX $1.02
  • VIVK $0.81
  • Average True Range (ATR)
  • SCYX 0.08
  • VIVK 0.08
  • MACD
  • SCYX 0.00
  • VIVK 0.03
  • Stochastic Oscillator
  • SCYX 51.70
  • VIVK 76.94

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About VIVK Vivakor Inc.

Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.

Share on Social Networks: